title: Questionnaire for biotechs: Vical incorporated.
abstract: This feature contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
authors.affiliation: a Igor Bilinsky is the Senior Vice President, Corporate Development, and Larry Smith is the Vice President, Vaccine Research of Vical Incorporated.
authors.forename: Igor P
authors.initials: IP
authors.lastname: Bilinsky
authors.forename: Larry R
authors.initials: LR
authors.lastname: Smith
mesh_terms: D001709:Biotechnology; D004345:Drug Industry; D006801:Humans; D011795:Surveys and Questionnaires; D013678:Technology, Pharmaceutical; D014612:Vaccines / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D014612:Vaccines